Literature DB >> 28555321

[Rare metabolic disorders and urolithiasis].

C Fisang1, N Laube2.   

Abstract

Numerous metabolic anomalies, which often have no direct pathological relevance when considered individually, are found in all people. In most patients with urinary tract stones, it can be assumed that a specific combination or interaction of these anomalies occurs, thus, resulting in stone formation, but only after individual exogenous risk factors are triggered. Lithogenesis is the result of a cascade of different "events" that are temporally close to one another, but sometimes these events interact strong enough that significant stone growth occurs. Chronic metabolic disorders usually lead to permanently altered urine compositions. The occurrence of physiological urine constituents in nonnormal concentration ratios and/or the nonphysiological excretion of metabolic products can significantly increase the lithogenicity of urine, so that urolithiasis can manifest itself as a clinical symptom. In cases of urolithiasis of unknown origin, a potentially hidden rare metabolic anomaly should always be considered. In addition, if a patient has a known metabolic disease, then this should always be taken into account as a risk factor for stone formation and attempts should be taken to clarify its influence on urine composition. This also applies to the efficacy of a therapy. A distinct link between a metabolic disease and stone formation is generally rare and will likely remain so despite significant advances regarding differential diagnosis and etiopathology. This article focuses on very rare metabolic causes and/or genetic syndromes which may be associated with urolithiasis. Patients receiving symptomatic stone treatment should receive life-long follow-up care from a urologist because reducing the recurrence rate helps to improve the quality of life of the patients.

Entities:  

Keywords:  Hypercalciuria; Lithogenesis; Quality of life; Urinary calculi; Urine composition

Mesh:

Year:  2017        PMID: 28555321     DOI: 10.1007/s00120-017-0415-3

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  18 in total

1.  Nephronophthisis.

Authors:  Roslyn J Simms; Lorraine Eley; John A Sayer
Journal:  Eur J Hum Genet       Date:  2008-12-10       Impact factor: 4.246

Review 2.  Paget's disease of bone.

Authors:  Gregory Gruener; Pauline Camacho
Journal:  Handb Clin Neurol       Date:  2014

Review 3.  Lesch-Nyhan Syndrome: Models, Theories, and Therapies.

Authors:  Scott Bell; Ilaria Kolobova; Liam Crapper; Carl Ernst
Journal:  Mol Syndromol       Date:  2016-09-24

4.  Clinical utility gene card for: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis with/without severe ocular involvement.

Authors:  Félix Claverie-Martín; Rosa Vargas-Poussou; Dominik Müller; Víctor García-Nieto
Journal:  Eur J Hum Genet       Date:  2014-09-03       Impact factor: 4.246

5.  Gitelman's syndrome revisited: an evaluation of symptoms and health-related quality of life.

Authors:  D N Cruz; A J Shaer; M J Bia; R P Lifton; D B Simon
Journal:  Kidney Int       Date:  2001-02       Impact factor: 10.612

6.  Renal xanthine stone in Lesch-Nyhan syndrome treated with allopurinol.

Authors:  A Ogawa; K Watanabe; N Minejima
Journal:  Urology       Date:  1985-07       Impact factor: 2.649

Review 7.  Cystic fibrosis in the era of precision medicine.

Authors:  Shruti M Paranjape; Peter J Mogayzel
Journal:  Paediatr Respir Rev       Date:  2017-03-09       Impact factor: 2.726

Review 8.  Idiopathic hypercalciuria and formation of calcium renal stones.

Authors:  Fredric L Coe; Elaine M Worcester; Andrew P Evan
Journal:  Nat Rev Nephrol       Date:  2016-07-25       Impact factor: 28.314

Review 9.  Lowe syndrome.

Authors:  Mario Loi
Journal:  Orphanet J Rare Dis       Date:  2006-05-18       Impact factor: 4.123

Review 10.  Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?

Authors:  Stephen Waldek; Sandro Feriozzi
Journal:  BMC Nephrol       Date:  2014-05-06       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.